Lin Chih-Hung, Kornhuber Johannes, Zheng Fang, Alzheimer Christian
Institute of Physiology and Pathophysiology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Department of Psychiatry, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Front Cell Neurosci. 2021 Apr 9;15:660561. doi: 10.3389/fncel.2021.660561. eCollection 2021.
The acid sphingomyelinase (ASM) converts sphingomyelin into ceramide. Recent work has advanced the ASM/ceramide system as a major player in the pathogenesis of major depressive disorder (MDD). Indeed, ASM activity is enhanced in MDD patients and antidepressant drugs like fluoxetine act as functional inhibitors of ASM. Here, we employed the specific ASM inhibitor ARC39 to explore the acute effects of the enzyme on hippocampal synaptic transmission and cell excitability in adult mouse brain slice preparations. In both field potential and whole-cell recordings, ARC39 (1-3 μM) enhanced excitatory synaptic input onto ventral hippocampal CA1 pyramidal cells. The specificity of drug action was demonstrated by its lacking effect in slices from ASM knockout mice. In control condition, ARC39 strongly reduced firing in most CA1 pyramidal cells, together with membrane hyperpolarization. Such pronounced inhibitory action of ARC39 on soma excitability was largely reversed when GABA receptors were blocked. The idea that ARC39 recruits GABAergic inhibition to dampen cell excitability was further reinforced by the drug's ability to enhance the inhibitory synaptic drive onto pyramidal cells. In pyramidal cells that were pharmacologically isolated from synaptic input, the overall effect of ARC39 on cell firing was inhibitory, but some neurons displayed a biphasic response with a transient increase in firing, suggesting that ARC39 might alter intrinsic firing properties in a cell-specific fashion. Because ARC39 is charged at physiological pH and exerted all its effects within minutes of application, we propose that the neurophysiological actions reported here are due to the inhibition of secretory rather than lysosomal ASM. In summary, the ASM inhibitor ARC39 reveals a tonic control of the enzyme over ventral hippocampal excitability, which involves the intrinsic excitability of CA1 pyramidal cells as well as their excitatory and inhibitory synaptic inputs.
酸性鞘磷脂酶(ASM)可将鞘磷脂转化为神经酰胺。近期研究使ASM/神经酰胺系统成为重度抑郁症(MDD)发病机制中的主要参与者。事实上,MDD患者的ASM活性增强,而氟西汀等抗抑郁药物可作为ASM的功能性抑制剂。在此,我们使用特异性ASM抑制剂ARC39来探究该酶对成年小鼠脑片制备中海马体突触传递和细胞兴奋性的急性影响。在场电位和全细胞记录中,ARC39(1 - 3 μM)增强了腹侧海马体CA1锥体神经元的兴奋性突触输入。药物作用的特异性通过其对ASM基因敲除小鼠脑片无影响得以证明。在对照条件下,ARC39使大多数CA1锥体神经元的放电强烈减少,并伴有膜超极化。当GABA受体被阻断时,ARC39对胞体兴奋性的这种显著抑制作用在很大程度上被逆转。ARC39增强对锥体神经元的抑制性突触驱动的能力进一步强化了其通过募集GABA能抑制来减弱细胞兴奋性的观点。在药理学上与突触输入隔离的锥体神经元中,ARC39对细胞放电的总体影响是抑制性的,但一些神经元表现出双相反应,放电有短暂增加,这表明ARC39可能以细胞特异性方式改变内在放电特性。由于ARC39在生理pH值下带电荷且在应用后几分钟内就发挥了所有作用,我们认为此处报道的神经生理作用是由于对分泌型而非溶酶体ASM的抑制。总之,ASM抑制剂ARC39揭示了该酶对腹侧海马体兴奋性的紧张性控制,这涉及CA1锥体神经元的内在兴奋性及其兴奋性和抑制性突触输入。